Zanubrutinib + Rituximab vs Bendamustine + Rituximab for Mantle Cell Lymphoma
(MANGROVE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Who Is on the Research Team?
Study Director
Principal Investigator
BeiGene
Are You a Good Fit for This Trial?
This trial is for people aged 70 or older, or those 60-69 with health issues preventing stem cell transplant. They must have untreated mantle cell lymphoma confirmed by tests, be able to perform daily activities (ECOG 0-2), and not have infections needing systemic treatment, CNS lymphoma involvement, plans for tumor debulking before a transplant, severe heart disease, bleeding disorders, or gastrointestinal problems affecting drug absorption.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either zanubrutinib plus rituximab or bendamustine plus rituximab. Zanubrutinib monotherapy continues until disease progression for Arm A, while Arm B is followed by observation.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bendamustine
- Rituximab
- Zanubrutinib
Bendamustine is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
BeiGene
Lead Sponsor